Stoke Therapeutics Inc (STOK)
Healthcare
Biotechnology
28.90 $
-3.9%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Stoke Therapeutics Inc (STOK)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 75.1% of the shares are freely tradable; institutional investors hold 120.3%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
120.3%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
3.8%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
75.1%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
19.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
62Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| RTW INVESTMENTS, LLC | 9.03 | 5,623,525 | +1.4 | 03/31/2026 |
| BlackRock Inc | 8.65 | 5,385,714 | +3.3 | 03/31/2026 |
| FMR Inc | 8.64 | 5,383,666 | -3.9 | 03/31/2026 |
| Lynx1 Capital Management, LP | 7.65 | 4,763,673 | -11.9 | 03/31/2026 |
| Redmile Group, LLC | 6.69 | 4,164,120 | +3.2 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 5.50 | 3,423,280 | -3.5 | 03/31/2026 |
| Baker Bros Advisors LP | 5.36 | 3,336,697 | +0.0 | 03/31/2026 |
| The Toronto-Dominion Bank | 5.10 | 3,173,258 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 5.06 | 3,149,239 | -0.5 | 12/31/2025 |
| Wellington Management Company LLP | 4.97 | 3,095,700 | +320.7 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.